Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 18, 2008, Pages 3231-3242

  Caldwell, David J ^a   Evans, Jeffery D ^b  

^a Department of Clinical and Administrative Sciences   (United States)

^b ULM College of Pharmacy   (United States)

Author keywords

CCR5; chemokine coreceptor antagonist; HIV 1 infection; maraviroc; UK 427857

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CYCLOHEXANE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MARAVIROC; TRIAZOLE DERIVATIVE;

DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; VIRUS REPLICATION;

ANTI-RETROVIRAL AGENTS; CYCLOHEXANES; DRUG THERAPY, COMBINATION; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CCR5; TREATMENT OUTCOME; TRIAZOLES; VIRUS REPLICATION;

EID: 59449093055     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656560802576324     Document Type: Article

References (59)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents Panel Roster. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf. [Last accessed on 23 August 2008[
2. European AIDS Clinical Society Executive Committee, European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe. Available from: http://www.eacs.eu/guide/index. htm [Last accessed 23 August 2008[
3. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection 2008 recommendations of the international AIDS Society-USA Panel. JAMA 2008;300(5):555-70
4. Isentress. EPARs for authorised medicinal products for human use. EMEA. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/isentress/ isentress.htm [Last accessed 24 August 2008[
5. Celsentri. EPARs for authorised medicinal products for human use. EMEA. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/celsentri/ celsentri.htm [Last accessed 24 August 2008[
6. Cox E. Maraviroc approval letter. Rockville, MD. Public Health Service. FDA/Department of Health and Human Services. Available from: http://www.fda.gov/cder/foi/appletter/2007/022128s000ltr.pdf [Last accessed 24 August 2008[
7. Cox E. Raltegravir approval letter. Rockville, MD. Public Health Service. FDA/Department of Health and Human Services. Available from: http://www.fda.gov/cder/foi/appletter/2007/022145s000tr.pdf [Last accessed 24 August 2008[
8. Cox E. Etravirine approval letter. Rockville, MD. Public Health Service. FDA/Department of Health and Human Services. Available from: http://www.fda.gov/cder/foi/appletter/2008/022187s000ltr.pdf [Last accessed 24 August 2008[
9. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis 2007;196:304-12
10. Landovitz RJ, Angel JB, Hoffman C, et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naïve subjects with HIV-1 infection. J Infect Dis 2008;198:1113-22
11. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49(11):4721-32
12. Kondru R, Zhang J, Ji C, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2006;73:789-800
13. Mayer H, Van Der Ryst E, Saag M, et al. Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experienced subjects infected with dual/mixed tropic HIV-1: 24-week results of a phase 2b exploratory trial. Program and abstracts of the XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract THLB0215. Available from: http://www.aids2006. org/PAG/Abstracts. aspx?AID = 50985 [Last accessed 13 Oct 2008[
14. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005;191:866-72
15. Abel S, Van Der Ryst E, Rosario MC, et al. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008;65(s1):5-18
16. Abel S, Russell D, Whitlock LA, et al. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 2008;65(s1):60-7
17. Abel S, Russell D, Taylor-Worth RJ, et al. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008;65(s1):27-37
18. Selzentry [package insert]. New York City, NY: Pfizer Inc; August 2007
19. Nelson M, Fätkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results [abstract 104aLB]. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, California. Available from: http://www.retroconference.org/2007/Abstracts/ 30636.htm [Last accessed 26 July 2008]
20. Lalezari J, Goodrich J, De Jesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada [abstract 104bLB]. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, California. Available from: http://www.retroconference. org/2007/Abstracts/ 30635.htm [Last accessed 26 July 2008]
21. Lalezari J, Mayer H, the MOTIVATE 1 Study Team. Efficacy and safety of maraviroc in antiretroviral treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week results of MOTIVATE 1 [abstract H-718a]. Program and abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, Illinois. Available from: http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly asp?CKey ={471F844E-DCF9-4D36-B713-6C6AC2D47CA8}& SKey = {5F5FCA3D-1CD2-4AA3-A93F- 73B4E8E75F71}& MKey ={D52CF5B5-E7A0-40B1-B430-CE0AC26BBA9E}& AKey ={32093528-52DC-4EBE-9D80-29DAD84C92CE}',%20500,%20400); [Last accessed 26 July 2008]
22. Fätkenheuer G, Konourina I, Nelson M, et al. Efficacy and safety of maraviroc (MVC) plus optimized background therapy (OBT) in viremic, antiretroviral treatment-experienced patients infected with CCR5-tropic (R5) HIV-1 in Europe, Australia and North America (MOTIVATE 2): 48-week results [abstract PS3/5]. 11th European AIDS Conference/EACS, Madrid, 2007. Available from: http://www.eacs.eu/conference/madrid07/pdf2.php?pdf=ABS00015 [Last accessed 26 July 2008]
23. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006;80(10):4909-20
24. Lewis M, Simpson P, Fransen S, et al. CXCR4-using virus detected in patients receiving maraviroc in the Phase III studies MOTIVATE 1 and 2 originates from a pre-existing minority of CXCR4-using virus [abstract 56]. Program and abstracts of the XVI HIV Drug Resistance Workshop; June 12-16, 2007; Barbados. Available from: http://www.intmedpress. com/Journal%20Management/ display.cfm? viewinfo =3F7451620345260A0143070F4 D22491C33782751545247000B5606510 B330C15050003421A484704 55096B00 [Last accessed 24 July 2008[
25. Van Der Ryst E, Westby M. Changes in HIV-1 co-receptor tropism for patients participating in the maraviroc MOTIVATE 1 and 2 clinical trials [abstract H-715]. Program and abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, Illinois. Available from: http://www.abstractsonline.com/viewer/ viewAbstractPrintFriendly.asp? CKey ={935091CF-D3E2-4A6C-A28C-FBC03FE760C7}& SKey ={5F5FCA3D-1CD2-4AA3-A93F-73B4E8E75F71}& MKey ={D52CF5B5-E7A0-40B1- B430-CE0AC26BBA9E}& AKey ={32093528-52DC-4EBE-9D80-29D [Last accessed 24 July 2008[
26. Mori J, Mosley M, Lewis M, et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2 [abstract 10]. Program and abstracts of the 16th International HIV Drug Resistance Workshop; June 12-16, 2007; Barbados. Available from: http://www.intmedpress. com/Journal%20Management/display.cfm? viewinfo = 3F7451620345260A0143070F4 D22491C33782751545247000B5606510 B330C15050003421A48470455096B00 [Last accessed 24 July 2008]
27. Kuhmann SE, Pugach P, Kunstman KJ, et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004;78(6):2790-807
28. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc vs efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: week 48 results of the MERIT study [abstract WESS104]. Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Available from: http://www.ias2007.org/pag/ Abstracts.aspx?SID =150& AID=5557 [Last accessed 24 July 2008[
29. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350:1850-61
30. Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-8
31. Heera J, Saag M, Ive P, et al. Virological correlates associated with treatment failure at week 48 in the Phase 3 study of maraviroc in treatment-naive patients [abstract 40LB]. Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Massachusetts. Available from: http://www.retroconference.org/2008/ Abstracts/33388.htm [Last accessed 24 July 2006[
32. Ribeiro RM, Hazenger MD, Perelson AS, Davenport MP. Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy J Virol 2006;80:802-9
33. Maraviroc tablets NDA 22-128. Antiviral Drugs Advisory Committee Briefing Document. April 24, 2007. Available from: http://www.fda.gov/OHRMS/DOCKETS/AC/ 07/briefing/2007-4283b1-01-Pfizer.pdf [Last accessed 24 July 2008[
34. Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008;52(3):858-65
35. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-10
36. Currier J, Boyd F, Burtcel B, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003;506-512
37. David MH, Hornung R, Fichtenbaum CJ. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis 2002;34:98-102
38. Fichtenbaum CJ. Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons. HIV Clin Trials 2004;5(6):416-33
39. De Jesus E, Walmsley S, Cohen C, et al. Fasted lipid changes after administration of maraviroc or efavirenz in combination with zidovudine and lamivudine for 48 weeks to treatment-naive HIV-infected patients [abstract 929]. Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Massachusetts. Available from: http://www.retroconference.org/2008/PDFs/929.pdf [Last accessed 25 July 2008[
40. Zaitseva MB, Lee S, Rabin RL, et al. CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection. J Immunol 1998;161:3103-13
41. Carrington M, Dean M, Martin MP, O'Brien SJ. Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Genet 1999;8(10):1939-45
42. Thomas SM, Tse DB, Ketner DS, et al. CCR5 expression and duration of high risk sexual activity among HIV-seronegative men who have sex with men. AIDS 2006;20(14):1879-83
43. Chalmet K, Van Wanzeele F, Demecheleer E, et al. Impact of Delta 32-CCR5 heterozygosity on HIV-1 genetic evolution and variability-a study of 4 individuals infected with closely related HIV-1 strains. Virology 2008;379(2):213-22
44. Gulick R, et al. ACTG 5211: Phase II study of the safety and efficacy of vicriviroc (VCV) in HIV+ treatment-experienced subjects: 48-week results [abstract TUAB102]. Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Available from: http://www.ias2007.org/pag/Abstracts.aspx?SID =48& AID=1623 [Last accessed 25 July 2008[
45. Glass WG, Mc Dermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile Virus Infection. J Exp Med 2006;203:35-40
46. Abel S, Russell D, Whitlock LA, et al. The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in health volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):47-53
47. Posniak AL, Boffito M, Russell D, et al. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. Br J Clin Pharmacol 2008;65(Suppl 1):54-9
48. Abel S, Russell D, Whitlock LA, et al. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/ levonorgestrel in health volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):19-26
49. Abel S, Jenkins TM, Whitlock LA, et al. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in health volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):38-46
50. Isentress [package insert]. Whitehouse Station, NJ: Merck; October 2007
51. Intelence [package insert]. Raritan, Inc: Tibotec Therapeutics; January 2008
52. Cooper RA, Gatell J, Rockstroh H, et al. 48-week results from BENCHMRK-1, a Phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1 [Poster 788]. Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Massachusetts. Available from: http://www. retroconference.org/2008/PDFs/788.pdf [Last accessed 17 Oct 2008[
53. Johnson M, Campbell T, Clotet B, et al. DUET-2: week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 591 treatment-experienced HIV-1-infected patients [Poster 791]. Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Massachusetts. Available from: http://www.retroconference.org/2008/PDFs/ 791.pdf [Last accessed 17 Oct 2008[
54. Zembower TR, Cerzenshtein L, Coleman K, Palella FJ. Severe rhabdomyolysis associated with raltegravir use [Correspondence]. AIDS 2008;22(11):1382-4
55. Low AJ, Marchant D, Brumme CJ, et al. CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. AIDS Res Hum Retroviruses 2008;24(2): 219-28
56. Dumond JB, Patterson KB, Pecha A, et al. Maraviroc pharmacokinetics in blood plasma, genital tract fluid, and tissue in healthy female volunteers [abstract 135LB]. Program and abstracts of the 15 th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Massachusetts. Available from: http://img.thebody.com/confs/retro2008/slides/135LB%20Dumond%20 slides.pdf [Last accessed on 13 Oct 2008[
57. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel singly-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007;512:566-75
58. Tressler R, Valdez H, Van Der Ryst E, et al. Comparison of results from the SensiTrop vs Trofile assays on 100 samples from the maraviroc expanded access program [abstract 920a]. Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Massachusetts. Available from: http://www.retroconference.org/2008/PDFs/920a.pdf [Last accessed 28 July 2008[
59. Reeves J, Han D, Wilkin T, et al. An enhanced version of the Trofile HIV co-receptor tropism assay predicts emergence of CXCR4 use in ACTG5211 vicriviroc trial samples [abstract 869]. Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Massachusetts. Available from: http://www.retroconference. org/2008/Abstracts/ 33252.htm [Last accessed on 28 July 2008]